An asymmetric synthesis of navaglitazar, a peroxisome proliferator activated receptor (PPAR) ? agonist, from commercially available (+)-methyl (2S,3R)-3-(4-methoxyphenyl)glycidate, is described. The new synthesis features high overall yield, low solvent usage, crystalline intermediates and operational simplicity.